This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, J. W. Articles by Brown, J. M. Search for Related Content PubMed PubMed Citation Articles by Evans, J. W. Articles by Brown, J. M.

Tirapazamine Is Metabolized to Its DNA-damaging Radical by Intranuclear Enzymes¹

Department of Radiation Oncology, Cancer Biology Research Laboratory, Stanford University School of Medicine, Stanford, California 94305

Tirapazamine (TPZ), a new anticancer drug that is currently in Phase II and III clinical trials, has a unique mechanism of action. Its cytotoxicity is selective for hypoxic cells in solid tumors and results from DNA damage produced by a free radical, which is generated by enzymatic reduction of the parent molecule. However, there is no agreement as to which enzyme(s) are involved. Here, we have measured both DNA damage and TPZ metabolism in A549 human lung cancer cells and in isolated nuclei derived from the cells. We show that, although the nuclei metabolize TPZ at a rate that is only 20% of that of whole cells, they have levels of DNA damage that are similar to those of the cells. We also show that TPZ radicals that are formed outside nuclei do not contribute to intranuclear DNA damage. Thus, essentially all of the DNA damage from TPZ results from radicals generated within the nucleus, and the 80% of the drug metabolism that occurs in the cytoplasm is probably irrelevant for the activity of this drug in killing hypoxic cells.

¹ This work was supported by NIH Grant CA 15201.

² Present address: Department of Orthopaedic Surgery, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, 930-01, Japan.

³ To whom requests for reprints should be addressed.

Received 6/ 6/97. Accepted 3/31/98.

This article has been cited by other articles:

				K. Hellauer, G. Lesage, A.-M. Sdicu, and B. Turcotte Large-Scale Analysis of Genes that Alter Sensitivity to the Anticancer Drug Tirapazamine in Saccharomyces cerevisiae Mol. Pharmacol., November 1, 2005; 68(5): 1365 - 1375. [Abstract] [Full Text] [PDF]

				B. Yang and C. P. Reynolds Tirapazamine Cytotoxicity for Neuroblastoma Is p53 Dependent Clin. Cancer Res., April 1, 2005; 11(7): 2774 - 2780. [Abstract] [Full Text] [PDF]

				R. L. Cowen, K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure Cancer Res., February 15, 2004; 64(4): 1396 - 1402. [Abstract] [Full Text] [PDF]

				K. O. Hicks, F. B. Pruijn, J. R. Sturman, W. A. Denny, and W. R. Wilson Multicellular Resistance to Tirapazamine Is Due to Restricted Extravascular Transport: A Pharmacokinetic/Pharmacodynamic Study in HT29 Multicellular Layer Cultures Cancer Res., September 15, 2003; 63(18): 5970 - 5977. [Abstract] [Full Text] [PDF]

				E. C. Chinje, R. L. Cowen, J. Feng, S. P. Sharma, N. S. Wind, A. L. Harris, and I. J. Stratford Non-Nuclear Localized Human NOSII Enhances the Bioactivation and Toxicity of Tirapazamine (SR4233) in Vitro Mol. Pharmacol., June 1, 2003; 63(6): 1248 - 1255. [Abstract] [Full Text] [PDF]

				B. Yang, N. Keshelava, C. P. Anderson, and C. P. Reynolds Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine Cancer Res., April 1, 2003; 63(7): 1520 - 1526. [Abstract] [Full Text] [PDF]

				K. B. Peters and J. M. Brown Tirapazamine: A Hypoxia-activated Topoisomerase II Poison Cancer Res., September 15, 2002; 62(18): 5248 - 5253. [Abstract] [Full Text] [PDF]

				K. B. Peters, H. Wang, J. M. Brown, and G. Iliakis Inhibition of DNA Replication by Tirapazamine Cancer Res., July 1, 2001; 61(14): 5425 - 5431. [Abstract] [Full Text] [PDF]

				D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 535 - 542. [Abstract] [Full Text] [PDF]

				B. G. Wouters, Y. M. Delahoussaye, J. W. Evans, G. W. Birrell, M. J. Dorie, J. Wang, D. MacDermed, R. K. Chiu, and J. M. Brown Mitochondrial Dysfunction after Aerobic Exposure to the Hypoxic Cytotoxin Tirapazamine Cancer Res., January 1, 2001; 61(1): 145 - 152. [Abstract] [Full Text]

				S. Y. Sharp, L. R. Kelland, M. R. Valenti, L. A. Brunton, S. Hobbs, and P. Workman Establishment of an Isogenic Human Colon Tumor Model for NQO1 Gene Expression: Application to Investigate the Role of DT-Diaphorase in Bioreductive Drug Activation In Vitro and In Vivo Mol. Pharmacol., November 1, 2000; 58(5): 1146 - 1155. [Abstract] [Full Text]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]